A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
NCT ID: NCT00144482
Last Updated: 2009-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
122 participants
INTERVENTIONAL
2003-12-31
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
NCT00144495
Erythropoietin and Iron Supplementation for Patients With Chemotherapy-induced Anaemia
NCT02731378
Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy
NCT00236951
A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer
NCT00269984
Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy
NCT02860598
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
recombinant human erythropoietin
36000IU（0.5mL）s.c./week for 8 weeks
2
recombinant human erythropoietin placebo
0 IU(0.5mL)s.c./week for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
recombinant human erythropoietin
36000IU（0.5mL）s.c./week for 8 weeks
recombinant human erythropoietin placebo
0 IU(0.5mL)s.c./week for 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* severe hypertension beyond control by drugs
20 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chugai Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chugai Pharmaceutical
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yoshiharu Ishikura
Role: STUDY_DIRECTOR
Chugai Pharmaceutical
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EPO307JP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.